UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 88

Sortiert nach

A perspective on modelling hepatitis C virus infection

Journal of viral hepatitis, 2010-12, Vol.17 (12), p.825-833

2010

Volltextzugriff (PDF)

Modeling vaccine and DAA treatment scale up effect on hepatitis C prevalence among persons who inject drugs in metropolitan Chicago

Journal of hepatology, 2017, Vol.66 (1), p.S505-S506

2017

Volltextzugriff (PDF)

Hepatitis C Viral Dynamics In vivo and the Antiviral Efficacy of Interferon-α Therapy

Science (American Association for the Advancement of Science), 1998-10, Vol.282 (5386), p.103-107

1998

Volltextzugriff (PDF)

Nucleic acid polymer REP2139 monotherapy reveals a short halflife of serum HBsAg in HBeAg+ chronically infected hepatitis B virus patients

Journal of hepatology, 2017, Vol.66 (1), p.S264-S264

2017

Volltextzugriff (PDF)

Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy

Journal of viral hepatitis, 2016-09, Vol.23 (9), p.708-717

2016

Volltextzugriff (PDF)

A phase 2 study exploring once daily dosing of ritonavir boosted lonafarnib for the treatment of chronic delta hepatitis – end of study results from the LOWR HDV-3 study

Journal of hepatology, 2017, Vol.66 (1), p.S101-S102

2017

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics Modeling of Lonafarnib in Patients with Chronic Hepatitis Delta Virus Infection

Journal of hepatology, 2016, Vol.64 (2), p.S589-S589

2016

Volltextzugriff (PDF)

Modeling Early HCV Kinetics to Individualize Direct Acting Antivirals Treatment Duration in Patients with Advanced Cirrhosis

Journal of hepatology, 2016, Vol.64 (2), p.S795-S795

2016

Volltextzugriff (PDF)

Hepatitis Delta Virus Kinetics under the Prenylation Inhibitor Lonafarnib Suggest HDV-Mediated Suppression of HBV Replication

Journal of hepatology, 2016, Vol.64 (2), p.S587-S587

2016

Volltextzugriff (PDF)

Differences in Viral Dynamics between Genotypes 1 and 2 of Hepatitis C Virus

The Journal of infectious diseases, 2000-07, Vol.182 (1), p.28-35

2000

Volltextzugriff (PDF)

558 HCV KINETICS DURING AND AFTER THE ANHEPATIC PHASE: IS THE LIVER THE PRIMARY SITE FOR HCV CLEARANCE?

Journal of hepatology, 2013-04, Vol.58, p.S229-S230

2013

Volltextzugriff (PDF)

808 MODELING HCV KINETICS DURING INTRAVENOUS SILIBININ MONOTHERAPY IN THE PERI-TRANSPLANT PERIOD

Journal of hepatology, 2013-04, Vol.58, p.S330-S331

2013

Volltextzugriff (PDF)

Dose-dependent decrease in hepatitis delta virus (HDV) RNA achieved with the oral prenylation inhibitor lonafarnib in a proof-of-concept, randomised, double-blinded, placebo-controlled study in patients with chronic HDV infection

Journal of clinical virology, 2015-08, Vol.69, p.247-247

2015

Volltextzugriff (PDF)

LP36 : Understanding hepatitis delta virus and HBsAG kinetics during treatment with prenylation inhibitor lonafarnib via mathematical modeling

Journal of hepatology, 2015-04, Vol.62, p.S281-S282

2015

Volltextzugriff (PDF)

Hepatocyte Proliferation and Hepatitis C Virus Kinetics During Treatment

Clinical pharmacology and therapeutics, 2011-03, Vol.89 (3), p.353-354

2011

Volltextzugriff (PDF)

507 MODELING HDV KINETICS DURING PEGYLATED INTERFERON-ALFA TREATMENT

Journal of hepatology, 2012-04, Vol.56, p.S200-S200

2012

Volltextzugriff (PDF)

1201 NEW INSIGHTS INTO THE MECHANISM OF ACTION OF INTERFERON-ALPHA AND BMS-790052: A MULTI-SCALE MATHEMATICAL MODELING APPROACH

Journal of hepatology, 2011-03, Vol.54, p.S474-S474

2011

Volltextzugriff (PDF)

776 MODELING INTERFERON-ALPHA MEDIATED INHIBITION KINETICS OF INTRACELLULAR AND EXTRACELLULAR HCVRNA DURING HCV INFECTION IN VITRO

Journal of hepatology, 2011-03, Vol.54, p.S312-S312

2011

Volltextzugriff (PDF)

Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patients

Journal of viral hepatitis, 2011-04, Vol.18 (4), p.e52-e60

2011

Volltextzugriff (PDF)

Modeling hepatitis C virus dynamics: Liver regeneration and critical drug efficacy

Journal of theoretical biology, 2007-07, Vol.247 (2), p.371-381

2007

Volltextzugriff (PDF)

Understanding the multiphasic viral kinetics of cute HBV infection observed in humanized uPA/SCID mice using an agent-based modeling approach

Journal of hepatology, 2018-04, Vol.68, p.S782-S783

2018

Volltextzugriff (PDF)

SAT-389 - Understanding the multiphasic viral kinetics of cute HBV infection observed in humanized uPA/SCID mice using an agent-based modeling approach

Journal of hepatology, 2018-04, Vol.68, p.S782-S783

2018

Volltextzugriff (PDF)

Mathematical modeling of viral kinetics under immune control during primary HIV-1 infection

Journal of theoretical biology, 2009-08, Vol.259 (4), p.751-759

2009

Volltextzugriff (PDF)

Antiviral action of ribavirin in chronic hepatitis C

Gastroenterology (New York, N.Y. 1943), 2004-03, Vol.126 (3), p.703-714

2004

Volltextzugriff (PDF)

Modeling serum HBsAg, HBV DNA and transaminase kinetics during REP 2139 monotherapy in chronic HBeAg+ HBV infection

Journal of hepatology, 2018-04, Vol.68, p.S508

2018

Volltextzugriff (PDF)

1 – 25 von 88

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(85)

Publikationsform

Sprache

Englisch
(88)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A perspective on modelling hepatitis C virus infection

Modeling vaccine and DAA treatment scale up effect on hepatitis C prevalence among persons who inject drugs in metropolitan Chicago

Hepatitis C Viral Dynamics In vivo and the Antiviral Efficacy of Interferon-α Therapy

Nucleic acid polymer REP2139 monotherapy reveals a short halflife of serum HBsAg in HBeAg+ chronically infected hepatitis B virus patients

Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy

A phase 2 study exploring once daily dosing of ritonavir boosted lonafarnib for the treatment of chronic delta hepatitis – end of study results from the LOWR HDV-3 study

Pharmacokinetics and Pharmacodynamics Modeling of Lonafarnib in Patients with Chronic Hepatitis Delta Virus Infection

Modeling Early HCV Kinetics to Individualize Direct Acting Antivirals Treatment Duration in Patients with Advanced Cirrhosis

Hepatitis Delta Virus Kinetics under the Prenylation Inhibitor Lonafarnib Suggest HDV-Mediated Suppression of HBV Replication

Differences in Viral Dynamics between Genotypes 1 and 2 of Hepatitis C Virus

558 HCV KINETICS DURING AND AFTER THE ANHEPATIC PHASE: IS THE LIVER THE PRIMARY SITE FOR HCV CLEARANCE?

808 MODELING HCV KINETICS DURING INTRAVENOUS SILIBININ MONOTHERAPY IN THE PERI-TRANSPLANT PERIOD

Dose-dependent decrease in hepatitis delta virus (HDV) RNA achieved with the oral prenylation inhibitor lonafarnib in a proof-of-concept, randomised, double-blinded, placebo-controlled study in patients with chronic HDV infection

LP36 : Understanding hepatitis delta virus and HBsAG kinetics during treatment with prenylation inhibitor lonafarnib via mathematical modeling

Hepatocyte Proliferation and Hepatitis C Virus Kinetics During Treatment

507 MODELING HDV KINETICS DURING PEGYLATED INTERFERON-ALFA TREATMENT

1201 NEW INSIGHTS INTO THE MECHANISM OF ACTION OF INTERFERON-ALPHA AND BMS-790052: A MULTI-SCALE MATHEMATICAL MODELING APPROACH

776 MODELING INTERFERON-ALPHA MEDIATED INHIBITION KINETICS OF INTRACELLULAR AND EXTRACELLULAR HCVRNA DURING HCV INFECTION IN VITRO

Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patients

Modeling hepatitis C virus dynamics: Liver regeneration and critical drug efficacy

Understanding the multiphasic viral kinetics of cute HBV infection observed in humanized uPA/SCID mice using an agent-based modeling approach

SAT-389 - Understanding the multiphasic viral kinetics of cute HBV infection observed in humanized uPA/SCID mice using an agent-based modeling approach

Mathematical modeling of viral kinetics under immune control during primary HIV-1 infection

Antiviral action of ribavirin in chronic hepatitis C

Modeling serum HBsAg, HBV DNA and transaminase kinetics during REP 2139 monotherapy in chronic HBeAg+ HBV infection

Suchergebnisse filtern